Combination erythropoietin-hydroxyurea therapy in sickle cell disease: experience from the National Institutes of Health and a literature review.

Little JA, McGowan VR, Kato GJ, Partovi KS, Feld JJ, Maric I, Martyr S, Taylor JG, Machado RF, Heller T, Castro O, Gladwin MT. Combination erythropoietin-hydroxyurea therapy in sickle cell disease: experience from the National Institutes of Health and a literature review. Haematologica. 2006 Aug; 91(8):1076-83.

View in: PubMed

subject areas

Anemia, Sickle Cell
Drug Therapy, Combination
Erythropoietin
Hematocrit
Humans
Hydroxyurea
National Institutes of Health (U.S.)
Recombinant Proteins
Treatment Outcome
United States

authors with profiles

James Taylor

RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support